Public health alert: Mpox clade I
Queensland Health has been notified of a confirmed case of overseas acquired mpox clade I in the Metro South region. Contacts have been identified and advised to seek vaccination and testing (if symptomatic) according to their individual risk.
See more mpox information on the Queensland Government website.
Differences between mpox clade I and clade II
Clade I is more likely than Clade II to cause severe disease and death, especially in immunocompromised people. The clinical presentation includes a prodromal illness characterised by fever, headache, myalgia and sore throat. Skin lesions develop typically 1 to 5 days after the onset of fever, and they can present as macules, vesicles or pustules.
Please see the Communicable Diseases Network Australia (CDNA)’s mpox guidelines for further information.
Information for mpox vaccine providers
There is good supply of funded mpox vaccine in Queensland. Vaccine providers can order additional stock by submitting a completed Immunisation Order Form to QHIP-ADMIN@health.qld.gov.au.
Access further details about mpox vaccination and eligibility in the Australian Immunisation Handbook mpox chapter.
More information for health professionals
For primary care assessment and management of mpox, see the Brisbane South HealthPathways mpox page.
For the latest mpox medical advice and official reports, please see the Department of Health, Disability and Ageing mpox webpage.
Further training, resources and community information is available through ASHM.